VIDEO: New trials expand treatment options for diabetes, CVD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LOS ANGELES — In this video exclusive, Robert P. Giugliano, MD, SM, FACC, FAHA, clinical cardiologist at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, presents an overview of recent trials from the Thrombolysis in Myocardial Infarction (TIMI) Study Group that advance the understanding of new therapies for diabetes, cardiovascular disease and beyond.

Giugliano, senior investigator with the TIMI Study Group, highlights a subgroup analysis of ENGAGE AF-TIMI 48, which compared the nonvitamin K antagonist oral anticoagulant edoxaban (Savaysa, Daiichi Sankyo) vs. warfarin in patients with and without diabetes; CAMELLIA-TIMI 61, which evaluated the weight-loss drug lorcaserin (Belviq, Eisai) vs. placebo in patients with diabetes and CVD; DECLARE-TIMI 58, which looked at the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) in patients with diabetes and CV risk; and the FOURIER and VESALIUS-CV trials of the PCSK9 inhibitor evolocumab (Repatha, Amgen) in various populations.

Watch the video for more.